Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 1
2010 1
2012 1
2013 2
2014 2
2015 4
2016 3
2017 6
2018 12
2019 18
2020 23
2021 17
2022 9
2023 12
2024 15
2025 7
2026 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

130 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.
Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, Diamond MP, Surrey E, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Rowan JP, Duan WR, Ng J, Schwefel B, Thomas JW, Jain RI, Chwalisz K. Taylor HS, et al. N Engl J Med. 2017 Jul 6;377(1):28-40. doi: 10.1056/NEJMoa1700089. Epub 2017 May 19. N Engl J Med. 2017. PMID: 28525302 Free article. Clinical Trial.
METHODS: We performed two similar, double-blind, randomized, 6-month phase 3 trials (Elaris Endometriosis I and II [EM-I and EM-II]) to evaluate the effects of two doses of elagolix - 150 mg once daily (lower-dose group) and 200 mg twice daily (higher-dose group) - …
METHODS: We performed two similar, double-blind, randomized, 6-month phase 3 trials (Elaris Endometriosis I and II [EM-I and EM-II]) …
Endometriosis: advances and controversies in classification, pathogenesis, diagnosis, and treatment.
Rolla E. Rolla E. F1000Res. 2019 Apr 23;8:F1000 Faculty Rev-529. doi: 10.12688/f1000research.14817.1. eCollection 2019. F1000Res. 2019. PMID: 31069056 Free PMC article. Review.
Endometriosis is an enigmatic disease that could start at birth. Its pathogenesis is supported by different theories. ...Special reference will be made to the quality of surgery and how to understand patients with endometriosis and endometriosis....
Endometriosis is an enigmatic disease that could start at birth. Its pathogenesis is supported by different theories. ...Special refe …
Elagolix in the treatment of endometriosis: impact beyond pain symptoms.
Archer DF, Soliman AM, Agarwal SK, Taylor HS. Archer DF, et al. Ther Adv Reprod Health. 2020 Dec 1;14:2633494120964517. doi: 10.1177/2633494120964517. eCollection 2020 Jan-Dec. Ther Adv Reprod Health. 2020. PMID: 33294846 Free PMC article. Review.
Elagolix is an oral gonadotropin-releasing hormone receptor antagonist that is approved for the management of moderate to severe pain associated with endometriosis. However, the benefits of elagolix extend beyond reducing pain symptoms. This article reviews t …
Elagolix is an oral gonadotropin-releasing hormone receptor antagonist that is approved for the management of moderate to severe pain …
A Clinician's Guide to the Treatment of Endometriosis with Elagolix.
Leyland N, Estes SJ, Lessey BA, Advincula AP, Taylor HS. Leyland N, et al. J Womens Health (Larchmt). 2021 Apr;30(4):569-578. doi: 10.1089/jwh.2019.8096. Epub 2020 Sep 22. J Womens Health (Larchmt). 2021. PMID: 32975461 Free PMC article. Review.
Elagolix, a nonpeptide, small-molecule gonadotropin-releasing hormone (GnRH) receptor antagonist, is the first new oral therapy to be approved for the treatment of endometriosis-associated pain in the United States in more than a decade. ...This review provides an o …
Elagolix, a nonpeptide, small-molecule gonadotropin-releasing hormone (GnRH) receptor antagonist, is the first new oral therapy to be …
Overview of elagolix for the treatment of endometriosis.
Melis GB, Neri M, Corda V, Malune ME, Piras B, Pirarba S, Guerriero S, Orrù M, D'Alterio MN, Angioni S, Paoletti AM. Melis GB, et al. Expert Opin Drug Metab Toxicol. 2016 May;12(5):581-8. doi: 10.1517/17425255.2016.1171316. Expert Opin Drug Metab Toxicol. 2016. PMID: 27021205 Review.
This article focuses on the data of the literature about elagolix, a novel non-peptidic GnRHantagonist, in the treatment of endometriosis. EXPERT OPINION: Elagolix demonstrated efficacy in the management of endometriosis-associated pain and had an acce …
This article focuses on the data of the literature about elagolix, a novel non-peptidic GnRHantagonist, in the treatment of endome …
Efficacy of elagolix in the treatment of endometriosis.
Perricos A, Wenzl R. Perricos A, et al. Expert Opin Pharmacother. 2017 Sep;18(13):1391-1397. doi: 10.1080/14656566.2017.1359258. Epub 2017 Jul 28. Expert Opin Pharmacother. 2017. PMID: 28737050 Review.
Much research has gone into developing medications that can be used to alleviate endometriosis-associated symptoms. In addition to already established medications, a new GnRH antagonist, elagolix, is in development. ...While elagolix may have an advantage ove …
Much research has gone into developing medications that can be used to alleviate endometriosis-associated symptoms. In addition to al …
Elagolix for endometriosis: all that glitters is not gold.
Vercellini P, Viganò P, Barbara G, Buggio L, Somigliana E; ‘Luigi Mangiagalli’ Endometriosis Study Group. Vercellini P, et al. Hum Reprod. 2019 Feb 1;34(2):193-199. doi: 10.1093/humrep/dey368. Hum Reprod. 2019. PMID: 30551159 Free article.
Elagolix, an orally active non-peptidic GnRH antagonist, has been approved by the Food and Drug Administration for the management of moderate to severe pain associated with endometriosis. ...Elagolix may thus be considered a novelty in terms of its endocrine …
Elagolix, an orally active non-peptidic GnRH antagonist, has been approved by the Food and Drug Administration for the management of …
Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis.
Shebley M, Polepally AR, Nader A, Ng JW, Winzenborg I, Klein CE, Noertersheuser P, Gibbs MA, Mostafa NM. Shebley M, et al. Clin Pharmacokinet. 2020 Mar;59(3):297-309. doi: 10.1007/s40262-019-00840-7. Clin Pharmacokinet. 2020. PMID: 31749075 Free PMC article. Review.
The clinical pharmacology of elagolix was extensively evaluated in clinical studies in healthy subjects and in women with endometriosis. ...These studies enabled a comprehensive understanding of elagolix mechanism of action and the downstream pharmacodynamic …
The clinical pharmacology of elagolix was extensively evaluated in clinical studies in healthy subjects and in women with endometr …
Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial.
Miller CE, Kim JH, Kroll R, Simon JA, Soliman AM, Thomas JW, Xu Y, Ng J, Snabes MC. Miller CE, et al. Am J Obstet Gynecol. 2024 Dec;231(6):630.e1-630.e13. doi: 10.1016/j.ajog.2024.06.040. Epub 2024 Jun 30. Am J Obstet Gynecol. 2024. PMID: 38955323 Free article. Clinical Trial.
BACKGROUND: Elagolix, an approved oral treatment for endometriosis-associated pain, has been associated with hypoestrogenic effects when used as monotherapy. ...RESULTS: A total of 679 patients were randomized to elagolix with add-back therapy (n=389), ela …
BACKGROUND: Elagolix, an approved oral treatment for endometriosis-associated pain, has been associated with hypoestrogenic ef …
Novel pharmacological therapies for the treatment of endometriosis.
Buggio L, Dridi D, Barbara G, Merli CEM, Cetera GE, Vercellini P. Buggio L, et al. Expert Rev Clin Pharmacol. 2022 Sep;15(9):1039-1052. doi: 10.1080/17512433.2022.2117155. Epub 2022 Aug 30. Expert Rev Clin Pharmacol. 2022. PMID: 36000243 Free article. Review.
INTRODUCTION: Endometriosis is a chronic, estrogen-dependent, inflammatory disease associated with pelvic pain, infertility, impaired sexual function, and psychological suffering. ...Further studies are needed to identify the ideal treatment for women with endometriosis …
INTRODUCTION: Endometriosis is a chronic, estrogen-dependent, inflammatory disease associated with pelvic pain, infertility, impaired …
130 results